Brazil ANVISA Issues Four Resolutions in October 2026: Rota-Strip Prohibition, BD Angiocath Recall, and Suspensions of Spinal and Ablation Devices

Event

On 23 October 2026, the Brazilian Health Regulatory Agency (ANVISA) published a set of medical device enforcement measures involving one in vitro diagnostic rapid test, three surgical implant and interventional devices, and one venous puncture catheter. ANVISA stated that the measures were published as resolutions in the Federal Official Gazette (DOU) on 21 October 2026 under numbers RE 4.151/2026, RE 4.153/2026, RE 4.154/2026 and RE 4.157/2026. The announcement divides the measures into three groups according to the basis for action, and the actions in the three groups are not the same.

Group 1: Rotavirus Rapid Test Prohibited by Manufacturing Date

The product named is Rota-Strip, a rapid diagnostic reagent for detecting rotavirus antigen. The announcement states that the manufacturer is Coris Bioconcept and that the inspection was carried out following an application by Nanosens Ltda. The conclusion was that products manufactured by the company did not comply with current regulations. The scope is defined by manufacturing date: test reagents manufactured from 9 February 2026 are suspended from sale, import, advertising and use.

Detail to note: The prohibition covers goods manufactured after that date, not all models and not all stock. Verification must be based on manufacturing date; judging only by batch-number prefix or arrival date can easily lead to omissions.

Group 2: Costa Rica Factory Inspection Leads to Three Products

The second group begins with an overseas factory inspection. From 2 to 5 February 2026, ANVISA inspected Precision Concepts Costa Rica S.A. (operating under the name Biomerics Alajuela) and found violations of ANVISA regulations and Law No. 6.437/1977.

On this basis, three products were recalled, also defined by manufacturing date, covering batches manufactured from 5 February 2026: Covidien's CLOSURERFS radiofrequency vein ablation needle, the Cavix cervical fusion cage, and the CORUS spinal system X-type cannula kit. The three products are also suspended from manufacture, sale, distribution, advertising and use. The announcement does not explain the specific correspondence between these three products and the inspection findings; it provides only the violation conclusion and the list of measures.

Group 3: BD Angiocath Due to Failed Surface Verification

The third group concerns BD Angiocath, manufactured by Becton Dickinson Indústrias Cirúrgicas Ltda, CNPJ No. 21.551.379/0001-06. The basis is a test report issued by the Ezequiel Dias Foundation (FUNED), which concluded that the product failed the surface verification test. ANVISA therefore required a recall and suspended sale, distribution and use of the product.

Differences in the Nature of the Three Categories of Measures

Viewed together, the intensity of the actions escalates. For the rapid test, sale, import, advertising and use are prohibited, effectively keeping products manufactured after that date out of the market. For the factory-violation group, recall plus suspension of manufacture and sale means both retrieving product and stopping new supply. For the catheter group, recall plus suspension of use places the focus on the user end.

The common point lies in how the boundary is drawn. All three groups use manufacturing date or test conclusion as the boundary, not the product model as a whole. This means earlier batches of the same model may still be in lawful circulation, while later batches must be withdrawn. When companies conduct inventory screening, a blanket approach by model may freeze compliant inventory together and leave affected batches on the shelf.

What the Announcement Does Not Say

The announcement does not provide affected quantities, distribution coverage, whether there have been related adverse events, or whether the batches concerned have left Brazil and entered other Mercosur countries. The full texts of the four resolutions were published in the DOU; during this verification, the DOU page could not be opened, so this article does not quote the resolution provisions and relies only on the wording of the ANVISA website announcement.

It should also be noted that ANVISA announcements are administrative enforcement information and are not equivalent to a judicial conclusion. Companies' handling of specific batches should still be based on the original resolutions and subsequent ANVISA notices.

An Easily Overlooked Time Span

The manufacturing start dates for all three groups fall in February 2026. By the time the announcement was published in October, more than eight months had passed. Products manufactured during this period are within the scope of the measures. For importers and hospitals, when the stock in the warehouse was manufactured is more important than when it arrived.

Sources and Scope Notes

Source

Source: Agência Nacional de Vigilância Sanitária (ANVISA), “Anvisa proíbe e determina recolhimento de dispositivos médicos,” published on 23 October 2026; the Federal Official Gazette resolutions cited on the same page are RE 4.151/2026, RE 4.153/2026, RE 4.154/2026 and RE 4.157/2026, published on 21 October 2026. Link: https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2026/anvisa-proibe-e-determina-recolhimento-de-dispositivos-medicos

Verification Scope and Access Date

The above ANVISA official announcement page was verified, with access on 29 October 2026 (Beijing time). Product names, manufacturers, inspection dates, manufacturing-date starting points, regulatory actions and resolution numbers are taken from the original announcement. The full-text DOU resolution pages were inaccessible during verification, so no provisions are quoted.

Scope Note

This article is an interpretation of publicly available regulatory information and does not constitute a conclusion or commitment regarding any specific product, company or registration application. The scope of affected batches, handling requirements and subsequent changes are subject to the ANVISA announcement and the original DOU resolutions. Information may change with subsequent official updates.

Information Sources

• ANVISA — Anvisa proíbe e determina recolhimento de dispositivos médicos, 2026-10-23: https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2026/anvisa-proibe-e-determina-recolhimento-de-dispositivos-medicos
• ANVISA — Notícias 2026: https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2026

AIMEILI Regulatory Interpretation

From a regulatory affairs perspective, the four resolutions illustrate three distinct enforcement tools: a product-specific prohibition for an IVD, a site-inspection-driven recall and suspension covering multiple implant and interventional products, and a test-report-driven recall and use suspension for a catheter. The most important operational point is that ANVISA scoped the measures by manufacturing date, not by product model or registration as a whole. Companies should therefore rely on batch-level traceability and verify the original DOU resolutions before making recall, stock or customer decisions.

• IVD enforcement: The Rota-Strip action is based on non-compliance with current regulations and covers sale, import, advertising and use. IVD manufacturers should confirm that manufacturing-date records and GMP compliance evidence are ready for inspection and that local representatives can support any suspension or recall.
• Foreign site inspection: The Precision Concepts Costa Rica action shows that an overseas manufacturing-site inspection can lead to recall and suspension across several product lines. The announcement does not map each product to specific findings, so companies should review supplier qualification, contract manufacturing agreements and foreign-site inspection readiness.
• Official laboratory testing: The BD Angiocath action follows a FUNED test report on surface verification. Companies should monitor official test methods, retain relevant test records and assess whether similar products or suppliers could be affected by comparable findings.
• Manufacturing-date scoping: Because the measures are not model-wide, a model-level stock freeze may be both over-inclusive and under-inclusive. Batch genealogy, distribution records and consignee traceability are essential to identify affected and compliant stock.
• Information limits: The announcement does not provide affected quantities, distribution coverage, adverse event information or Mercosur circulation details, and the DOU full texts were not accessible during verification. Companies should treat the public announcement as enforcement intelligence and confirm obligations against the original resolutions and any subsequent ANVISA communication.

Business Impact

• Manufacturers: Review Brazilian registration and local representative arrangements; map affected product families and manufacturing dates; assess whether recall, field safety corrective action, customer notices or ANVISA notifications are required; and confirm supplier and contract manufacturing site inspection readiness.
• Distributors and importers: Segregate stock by manufacturing date; do not rely only on batch prefix or arrival date; suspend sale, distribution, advertising or use as applicable; preserve distribution records for traceability; and communicate promptly with hospitals and clinics.
• CROs and regulatory affairs teams: Update regulatory intelligence and impact assessments; check whether similar products, manufacturing sites or test methods are used in other markets; and strengthen post-market surveillance, recall procedures and foreign-site audit readiness.
• Cross-border considerations: The announcement does not state whether affected batches left Brazil or entered other Mercosur countries. Companies should check export records and notify relevant affiliates or distributors where required.